Close
Presentations (slides, Video) and Abstract are available to GBCC Sign-up members.
You can access after log-in.
Program
Scientific Program
Program at a Glance
Scientific Program
Invited Speakers
09:00-10:15
  • Symposium 1: 
    Recent Strategies for ER+/HER2- Breast Cancer6
  • Venue:  RM 1(Vista 1+2)
Speakers
  • Optimal Duration of Adjuvant Therapy for HR+ Breast Cancer
    Louis Chow
     (Organization for Oncology and Translational Research, Hong Kong)
  • The Role of CDK4/6 Inhibitors in ER+/HER2- Early Breast Cancer
    Tadahiko Shien
     (Okayama Univ. Hospital, Japan)
  • ER+/HER2 Negative Premenopausal Breast Cancer- The Biomarker Way Forward
    Peter C. Dubsky
     (Hirslanden Klinik St. Anna, Switzerland)
  • Panel Discussion 1: 
    How to Manage Old-aged Breast Cancer Patients?15
  • Venue:  RM 2(Vista 3)
Speakers
  • Screening and Assessment of Breast Cancer in Older Women
    TBD
     (, )
  • Systemic Therapy for Older Breast Cancer Patients
    Jee Hyun Kim
     (Seoul National Univ. Bundang Hospital, Korea)
  • Surgical Therapy for Older Breast Cancer Patient
    TBD
     (, )
  • Education Session 1: 
    Radiologist’s Perspectives on Neoadjuvant Systemic Therapy in Breast Cancer21
  • Venue:  RM 3(Walker Hall 1)
Speakers
  • Causes of Over- and Underestimation of Tumor and Axillary LN After Neoadjuvant System Therapy
    Beatriu Reig
     (NYU Langone Health, U.S.A.)
  • Evaluation of Response to Neoadjuvant Systemic Therapy: Multiparametric Approach for Accurate Evaluation of Residual Tumor
    Masako Kataoka
     (Kyoto Univ., Japan)
  • How to Manage Residual Microcalcifications After Neoadjuvant Chemotherapy
    Sung Hun Kim
     (The Catholic Univ. of Korea, Seoul St. Mary's Hospital, Korea)
  • Oral Presentation 1
    51
  • Venue:  RM 4(Walker Hall 2)
  • GBCC-SSO Joint Session
    41
  • Venue:  RM 5(Art Hall)
10:30-11:45
  • Symposium 2: 
    HER2-Low as a Targetable Subset of Breast Cancer7
  • Venue:  RM 1(Vista 1+2)
Speakers
  • Is HER2-Low Breast Cancer an Independent/Distinctive Subtype?
    Naoto Ueno
     (MD Anderson Cancer Center, U.S.A.)
  • How to Identify HER2-Low Breast Cancer
    TBD
     (, )
  • Targeting HER2-Low and the Treatment Sequence
    Wei-Pang Chung
     (National Cheng Kung Univ. Hospital, Taiwan)
  • Panel Discussion 2: 
    Various Considerations in Premenopausal Breast Cancer Patients16
  • Venue:  RM 2(Vista 3)
Speakers
  • The Optimal Endocrine Combination with OFS
    Hee Jeong Kim
     (ASAN Medical Center, Korea)
  • Targeted Therapy for High-risk Patients and gBRCA Mutation Patients
    Hee Kyung Ahn
     (Gachon Univ. Gil Medical Center, Korea)
  • Prophylactic Mastectomy
    Eric Schneider
     (Yale School of Medicine, U.S.A.)
  • Education Session 2: 
    Genomic Assays and Treatment Decision22
  • Venue:  RM 3(Walker Hall 1)
Speakers
  • Optimal Decisions on Adjuvant Endocrine and Chemotherapy Using Multigene Assays
    TBD
     (, )
  • Clinical Parameters as Alternatives to Genomic Assays
    Jong Won Lee
     (ASAN Medical Center, Korea)
  • Interpretation of Genomic Assays in Premenopausal Women
    Kevin Kalinsky
     (Winship Cancer Institute of Emory Univ., U.S.A.)
  • Oral Presentation 2
    52
  • Venue:  RM 4(Walker Hall 2)
  • GBCC-JBCS Joint Session
    42
  • Venue:  RM 5(Art Hall)
12:00-12:45
  • Plenary Lecture 1
    1
  • Venue:  RM 1(Vista 1+2)
Speakers
  • TBD
    Ian Krop
     (Yale School of Medicine, U.S.A.)
13:00-13:45
  • Satellite Symposium 1: 
    MSD Korea45
  • Venue:  RM 1(Vista 1+2)
14:00-14:45
  • Plenary Lecture 2
    2
  • Venue:  RM 1(Vista 1+2)
Speakers
  • Fertility Issues in Young Breast Cancer Patients
    Sibylle Loibl
     (GBG Forschungs GmbH, Germany)
15:00-16:15
  • Panel Discussion 3: 
    Optimal Surgical Treatment After Neoadjuvant Chemotherapy17
  • Venue:  RM 2(Vista 3)
Speakers
  • Avoiding Breast Surgery in Patients with Radiologic Complete Response
    Joerg Heil
     (Brustzentrum Heidelberg, Klinik St. Elisabeth, Germany)
  • De-escalation of Sentinel Lymph Node Biopsy in Patients with Radiologic Complete Response
    TBD
     (, )
  • De-escalation of Radiotherapy in Patients Achieved Pathologically Complete Response
    Yeon-Joo Kim
     (National Cancer Center, Korea)
  • Symposium 3: 
    Beyond CDK4/6 Inhibitor: New Target and New Drugs8
  • Venue:  RM 3(Walker Hall 1)
Speakers
  • Novel Oral SERD and its Implication in Clinical Practice
    Yen-Shen Lu
     (National Taiwan Univ. Hospital, Taiwan)
  • Treatment Strategy After Progression on CDK4/6 Inhibitor
    Nadia Harbeck
     (LMU Univ. Hospital, Germany)
  • New Targets Beyond CDK4/6 Inhibitor: Development in Progress
    Yong Wha Moon
     (CHA Bundang Medical Center, Korea)
  • Oral Presentation 3
    53
  • Venue:  RM 4(Walker Hall 2)
  • GBCC-TBCS Joint Session
    43
  • Venue:  RM 5(Art Hall)
16:30-17:45
  • Education Session 3: 
    Special Issues in Young Women with Breast Cancer Treated with Radiotherapy23
  • Venue:  RM 2(Vista 3)
Speakers
  • Breast Radiotherapy During Pregnancy
    Stefanie Corradini
     (Univ. Hospital, LMU Munich, Germany)
  • Risk of Contralateral Breast Cancer After Breast Radiotherapy in Young Women
    Seung Won Seol
     (Univ. of Pennsylvania, U.S.A.)
  • Heart Disease After Breast Radiotherapy in Young Women
    Ji Hyeon Joo
     (Pusan National Univ. Yangsan Hospital, Korea)
  • Symposium 4: 
    Tailored Surgery in Early-stage Breast Cancer9
  • Venue:  RM 3(Walker Hall 1)
Speakers
  • Individualized Surgical Extent and Lumpectomy Margin in Early-stage Breast Cancer: Does Tumor Histology and Subtype Matter?
    Naoki Hayashi
     (Showa University School of Medicine, Japan)
  • The Role of Axillary Surgery for DCIS and Early-stage Breast Cancer
    Wonshik Han
     (Seoul National Univ. Hospital, Korea)
  • Pre-operative Genomic Assay for Breast Surgery Guidance in HR+/HER2- Breast Cancer
    TBD
     (, )
  • Oral Presentation 4
    54
  • Venue:  RM 4(Walker Hall 2)
  • GBCC-CACA Joint Session
    44
  • Venue:  RM 5(Art Hall)



Global Breast Cancer Conference Secretariat

Partner I INTERCOM Convention Services, Inc. (Core PCO)

TOP